Please enable JavaScript or talk to your local administrator to get JavaScript enabled.
Skip filters
Skip facets
  • 275

  • 206

  • 40

  • 34

  • 26

  • 23

  • 21

  • 19

  • 19

  • 17

Funder Group
Research Organization
FOR (ANZSRC) Category
RCDC Category
Country of Funder
Start Year
Active Year
Similar Projects for


Novel 3D personalized bladder cancer model on demand: A new era for personalized medicine.

Funder: Canadian Institutes of Health Research

Funding period
CAD 186 K
USD 141 K
Funding amount
Bladder cancer (BC) is the 5th most commonly diagnosed cancer in Canada. It is usually manifested as 'superficial' BC. However, 25% of patients progress to a more aggressive and potentially lethal state. Recent studies of BC have revealed several distinct subtypes emphasising the need for an individualized approach. Our group has successfully established a bladder cell removal (decellularization) protocol. These acellular bladders have been seeded with normal bladder cells and grown for up to 1 month showing adequate cell survival. These preliminary results proved to us the feasibility and great potential of engineering bladder tissues. Here we propose to develop a 3D BC model, on demand, using acellular bladder scaffolds as a platform, which will enable us to recreate a BC of a specific patient to test and/or develop drugs. The development of this model will potentially make a step forward on how we currently test anti-cancer drugs. Each 3D BC tissue constructed, will be identical to a specific patient undergoing bladder cancer. This approach will have the potential to simultaneously test multiple anti-cancer drugs before giving the appropriate one to the patient, avoiding sequential unnecessary treatments and reducing side effects which will ultimately improve patient's quality of life. Our model system is a novel approach that will aid in: the mechanistic studies of cell-cell interaction; provide a platform to test and develop new drugs; reduce the number of animals used for experimentation; and, provide a model for preclinical treatment evaluation before deciding on a personalized therapy. At the conclusion of this project we hope to have developed a new tool that will significantly impact the way we currently treat bladder cancer patients.

USD 435.5 M
Aggregated funding amount
USD 551 K
Average funding amount
Project list item
Recombinant CCL2 as a novel treatment strategy for bladder cancer

Bladder Cancer Advocacy Network to Neelam Mukherjee, Robert Scott Svatek

USD 50,000
2019 - 2020
Project list item
Understanding the Burden and Impact of Financial Toxicity in Bladder Cancer: A Mixed Methods Study of 2 Diverse Patient Populations

Bladder Cancer Advocacy Network to Sumeet Kaur Bhanvadia, Siamak Daneshmand, Reginald Tucker-Seeley

USD 50,000
2019 - 2020
Project list item
Quantifying Risk and Resilience (R2) among Patients with Bladder Cancer: A Novel Personalized, Comprehensive Risk Stratification Program

Bladder Cancer Advocacy Network to Sarah Psutka, Jonathan Wright, Daniel Lin, John Gore, Ryan O'Malley, Anne Browning, Florian Fintelmann

USD 50,000
2019 - 2020
Project list item
Targeting FGF in Bladder cancer after Neoadjuvant Immunotherapy and Surgery

American Association For Cancer Research to Joshua James Meeks

USD 25,000
2019 - 2020
Project list item
Biomarker-Based Tools for Treatment Response Decision Support of Bladder Cancer


USD 653,319
2019 - 2024
Project list item
Refined phenotyping and personalized targeting of muscle-invasive bladder cancer

Swiss National Science Foundation to Roland Seiler, Vera Genitsch, Franziska Singer, Kiu Yan Charlotte Ng, Marianna Kruithof-de Julio

USD 597,404
2019 - 2023
Project list item
DNA adductome of human bladder from the tobacco exposome

National Institute of Environmental Health Sciences to ROBERT J. TURESKY

USD 467,974
2019 - 2023
Project list item
New zebrafish-based methods for prediction of cisplatin response in bladder cancer

VINNOVA to Lasse Jensen

USD 33,577
2019 - 2019
Project list item
Combatting Bladder Cancer by Inducing Epithelial Turnover

National Cancer Institute to SOMAN N ABRAHAM

USD 203,510
2019 - 2021
Project list item
Chromatin Modifier Gene Mutation and Enhancer Dysfunction in Bladder Cancer

National Cancer Institute to BYRON H LEE

USD 243,205
2019 - 2024
Project list item
Raman Endoscopic Proteo-lipidomics of Bladder Cancer

European Research Council to Mads SYLVEST BERGHOLT

USD 1,705,861
2019 - 2024
Project list item
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)

National Cancer Institute to NOAH M HAHN

USD 656,816
2019 - 2024
Project list item
Development of an automated method to capture bladder cancer recurrence and progression for epidemiologic research

National Cancer Institute to KIM N DANFORTH

USD 172,270
2019 - 2021
Project list item
Defining the impact of intra-tumoral morphologic, immune and mutational heterogeneity in urothelial carcinoma

National Cancer Institute to HIKMAT AL-AHMADIE

USD 410,835
2019 - 2024
Project list item
Multi4 - a new surgical instrument for diagnosis and treatment of bladder cancer within cystoscopy

VINNOVA to Miden Melle-Hannah

USD 55,963
2019 - 2019
Project list item
The role of a new molecular driver in bladder cancer

National Cancer Institute to DALEY MORERA

USD 45,016
2018 - 2021
Project list item
Identifying DNA Biomarkers of Bacillus Calmette-Guerin (BCG) Resistance in Non-Muscle-Invasive Bladder Cancer

Canadian Institutes of Health Research to Jack Victor Warren Bacon, Alexander William Wyatt

USD 847
2018 - 2019
load more...